
Dyslipidemia
Latest News
Latest Videos

CME Content
More News

A multidisciplinary clinical forum discussed diagnosis, referral thresholds, and the evolving APOC3-targeted treatment landscape for FCS.

FDA approved once-daily oral enlicitide to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on FDA approvals, trial readouts, and key clinician insights across the cardiology specialty.

Leiter discusses the growth of incretin-based therapies through all aspects of the cardio-kidney-metabolic syndrome space.

Leiter discusses the importance of earlier and more dramatic lipid-lowering interventions in patients with diabetes at risk of cardiovascular disease.

Rishi Wadhera, MD, MPP, MPhil, addresses performance metrics, cross-specialty prescribing, and the policy forces reshaping the cardiometabolic care cascade.

The US FDA has approved olezarsen as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with severe hypertriglyceridemia.

Rishi Wadhera, MD, MPP, MPhil, discusses where the cardiometabolic care cascade is failing most consequentially at the 10th Annual Heart in Diabetes Meeting.

A Family Heart Database analysis found only 1.1% of US adults have undergone lipoprotein(a) testing.

Lilly reports dose-dependent PCSK9 and LDL-C reductions with single-dose VERVE-102 in interim phase 1b hypercholesterolemia data.

Saseen discusses the current dyslipidemia treatment landscape, highlighting current challenges and potential paths forward.

Blaha discusses his study analyzing nonstatin prescriptions from 2019-2024, highlighting the need for further clinical implementation of modern guidelines.

Catapano discusses the superior reduction in LDL-C, ApoB, and non-HDL-C demonstrated by enlicitide, suggesting its role as an add-on for LDL-C lowering.

Catch up on major trial results, groundbreaking guideline updates, and more.

March 2026 cardiology updates feature key ACC.26 data, new guidelines, and advances in PAH, AF, hypertension, and lipid management.

Navar discusses the phase 3 CORALreef AddOn trial, highlighting enlicitide’s superiority to ezetimibe, bempedoic acid, and a combination of both.





















































